Clinical trial
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a…
NCT00197015 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197015 |
|---|---|
| Title | Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children |
| Official title | Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis A |
| Intervention type | Biological |
| Interventions | Havrix®, M-M-R®II, VARIVAX® |
| Enrollment | 1,474 |
| Start date | Oct 6, 2003 |
| Primary completion | Jun 9, 2009 |
| Completion | Jun 9, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Jul 31, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: